Patients diagnosed with advanced renal cell carcinoma, who have received prior treatment with anti-angiogenic agents, now have the option of being treated with the small molecule inhibitor cabozantinib.
Patients diagnosed with advanced renal cell carcinoma (RCC), who have received prior treatment with anti-angiogenic agents, now have the option of being treated with cabozantinib (Cabometyx), following its FDA approval.
A small molecule inhibitor that binds c-Met and VEGFR2, cabozantinib was granted orphan drug designation in 2011. The first approval for the drug was a year later, for the treatment of a rare form of thyroid cancer, but the drug failed to improve outcomes in patients with prostate cancer.
Today’s approval follows the results of the phase 3 METEOR trial that met its primary endpoint of progression-free survival (PFS) in 330 patients diagnosed with advanced RCC. The randomized controlled trial compared cabozantinib with the standard of care therapy, everolimus, which is currently used as second-line for RCC. Cabozantinib treatment resulted in a 42% reduction in the rate of disease progression or death compared with everolimus. Further, a significant advantage in PFS was observed with cabozantinib (7.4 months) compared with everolimus (3.8 months) (HR, 0.58; 95% CI 0.45-0.74, P<.0001).
Most importantly, and significant to today’s approval, was recent data that proved a survival advantage of cabozantinib: median overall survival in the intent-to-treat population was 21.4 months, compared with 16.5 months for patients treated with everolimus (HR, 0.66; 95% CI, 0.53-0.83; P = .0003).
“With today’s announcement, patients with previously treated advanced kidney cancer now have a new option, the first and only approved product demonstrated to help patients live longer while also delaying the progression of their cancer,” said Michael M. Morrissey, PhD, president and CEO of Exelixis, the company that has developed cabozantinib, in a press release. “We are proud to bring new hope to this community, who are looking for more therapies that can help extend lives. Exelixis is committed to making Cabometyx available to patients in need within the next couple weeks.”
Most common adverse events (AEs) associated with the drug include diarrhea, fatigue, nausea, decreased appetite, palmar-plantar erythrodysesthesia syndrome, hypertension, vomiting, weight decreased, and constipation. Serious AEs were reported in 40% of patients, the most common being abdominal pain, pleural effusion, diarrhea, and nausea.
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More
Low-Volume Hospitals Had Higher Reoperation Rate, Postoperative Complications in CRC
April 18th 2024Patients opting for elective colorectal surgery to address colorectal cancer (CRC) could have different rates of reoperation and postoperative complications based on the size of the hospital.
Read More